Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 2

Status

Recruiting 3Withdrawn 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 120Head & Neck 75Thoracic 62Other solid neoplasm 36Breast 34Genitourinary 31Gynecologic 18Dermatologic 15Sarcoma 8Tumor-Agnostic 7Lymphoid 6Other neoplasm 3Endocrine 2CNS 2NET 1

Conditions

Neoplasms 7

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × toripalimab × Tumor-Agnostic × Clear all
NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Tumor-Agnostic

Neoplasms

NCT07004244 2025-06-24

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Sichuan University

Phase 1 Recruiting
20 enrolled
Tumor-Agnostic

Neoplasms

NCT04991506 2025-06-23

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Elpiscience Biopharma, Ltd.

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

NCT05615974 2024-12-19

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

LaNova Medicines Limited

Phase 1/2 Recruiting
139 enrolled
Tumor-Agnostic

Neoplasms

NCT06612632 2024-09-25

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT06389526 2024-09-19

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Coherus Oncology, Inc.

Phase 1 Not yet recruiting
48 enrolled
Tumor-Agnostic

Neoplasms

NCT05253105 2022-05-31

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡